TY - JOUR
T1 - Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent
AU - Adjei, Alex A.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2004/7/15
Y1 - 2004/7/15
N2 - Pemetrexed (ALIMTA, LY231514, MTA) is a novel antimetabolite that inhibits at least three enzymes involved in the folate pathway. These enzymes are thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has demonstrated clinical activity in non-small cell lung cancer as well as in a broad array of other solid tumors, including mesothelioma, breast, colorectal, bladder, cervical, gastric and pancreatic cancer. In non-small cell lung cancer, single-agent activity has been documented in the first- and second-line settings in Phase II and Phase III trials. Promising activity has also been demonstrated when pemetrexed is combined with platinum compounds (cisplatin, carboplatin, and oxaliplatin), vinorelbine, and gemcitabine. Low level dietary supplement of folic acid and vitamin B12 has significantly decreased the mucosal and bone marrow toxicity of pemetrexed without compromising its antitumor effect.
AB - Pemetrexed (ALIMTA, LY231514, MTA) is a novel antimetabolite that inhibits at least three enzymes involved in the folate pathway. These enzymes are thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed has demonstrated clinical activity in non-small cell lung cancer as well as in a broad array of other solid tumors, including mesothelioma, breast, colorectal, bladder, cervical, gastric and pancreatic cancer. In non-small cell lung cancer, single-agent activity has been documented in the first- and second-line settings in Phase II and Phase III trials. Promising activity has also been demonstrated when pemetrexed is combined with platinum compounds (cisplatin, carboplatin, and oxaliplatin), vinorelbine, and gemcitabine. Low level dietary supplement of folic acid and vitamin B12 has significantly decreased the mucosal and bone marrow toxicity of pemetrexed without compromising its antitumor effect.
UR - http://www.scopus.com/inward/record.url?scp=3042575322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3042575322&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-040010
DO - 10.1158/1078-0432.CCR-040010
M3 - Article
C2 - 15217974
AN - SCOPUS:3042575322
SN - 1078-0432
VL - 10
SP - 4276s-4280s
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12 II
ER -